Malignant Liver Lesions

Please sign in to your myUEG account to begin this course now

Liver cancer is the sixth most common cancer in the world, but the lack of appropriate prevention and surveillance programs, as well as the need for more effective curative treatments, means it ranks second on the list of cancer-related deaths. As such, over the past few years, clinicians and medical researchers have tried to develop and/or implement more accurate means of surveillance and diagnosis, improved staging systems, novel therapeutic approaches and refined liver transplantation guidelines. 

This online course addresses the most relevant aspects pertaining to hepatocellular carcinoma (HCC), which is the most frequent primary liver cancer. Topics covered range from aetiology, epidemiology, diagnosis and staging to locoregional and medical therapies, with emphasis on liver transplantation.

This course was developed by: UEG.

  • To become familiar with current epidemiologic data on HCC and its underlying causes and risk factors. 
  • To understand the importance of surveillance programs, and become acquainted with the most recent diagnosis and staging criteria for HCC.
  • To be able to identify and decide on the most appropriate criteria for liver transplantation for HCC and downstaging/bridging therapies, as well as to identify key issues related with recurrence, adjuvant therapies and organ shortage, in a transplantation setting. 
  • To learn about the different locoregional and medical therapies currently available for HCC, as well as prospective new treatments. 

Editor, UEG E-learning
Rui Castro, The Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Portugal.

Lead author:
Helen Reeves, Senior Lecturer and Honorary Consultant Gastroenterologist at Newcastle Hospitals NHS Foundation Trust, Newcastle University, United Kingdom. 

Jean-Francois Dufour, Full Professor of Hepatology; Physician-in-Chief and Clinic Director at the University Clinic for Visceral Surgery and Medicine, Bern, Switzerland.

Patrizia Burra, Associate Professor of Gastroenterology and Head of the Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology at Padova University Hospital, Padua, Italy.

Markus Peck, Chair of the Department of Gastroenterology, Hepatology, Endocrinology and Nephrology at the Klagenfurt am Wörthersee Clinic, Austria. 

Dina Tiniakos, Clinical Senior Lecturer and Honorary Consultant in Cellular Pathology at Newcastle Hospitals NHS Foundation Trust, Newcastle University, United Kingdom.

This course is suitable for practicing hepatologists, as well as liver pathologists, nurses and any other healthcare professionals interested in malignant liver lesions, particularly HCC.  

  • The course is designed to last approximately 2 hours and 30 minutes in total. 
  • All authors and the course editor have declared that they have no conflicts of interest in relation to the material in this course. 
  • The production of this course was funded entirely by UEG. No external sponsorship was received.
  • The material used in this course was prepared in 2016–2017.
  • Learners are invited to test their knowledge throughout the course via a series of MCQs.
  • The post-course assessments have a pass mark of 70%. Those scoring less than the required pass mark are encouraged to revisit the corresponding Module and retake the assessment. Upon successful completion, learners will be able to download a high-quality infographic summary of the course.

Release Date: March 2017